Tag: Protease inhibitor

Nelfinavir, an antiretroviral medication used to treat human immunodeficiency virus (HIV) infection, was first approved by the FDA in 1997. The generic for nelfinavir is known by its chemical name, nelfinavir mesylate, but a therapeutically equivalent generic version is currently not available in the United States.

Nelfinavir, an antiretroviral medication approved by the FDA in 1997, is not an antibiotic but a protease inhibitor used in the treatment of human immunodeficiency virus (HIV). This distinction is crucial for understanding how the drug works and why it targets viral infections rather than bacterial ones.

Originally developed as a potent HIV protease inhibitor in the 1990s, ritonavir's primary use has evolved significantly, and it is now most commonly used at low doses to boost the effectiveness of other medications. Its profound impact on drug metabolism is the key to understanding what does ritonavir do in the body today.

First approved by the FDA in 2003, atazanavir (brand name Reyataz) is an antiretroviral medication from the protease inhibitor class used to treat human immunodeficiency virus (HIV) infection. By blocking a critical enzyme the virus needs to mature, it helps decrease the amount of HIV in the blood.

First approved by the FDA on **June 20, 2003**, atazanavir (Reyataz) marked a significant advancement in HIV treatment as the first once-daily protease inhibitor for adults. The answer to the question 'when was atazanavir FDA approved?' highlights a key moment in the evolution of antiretroviral therapy and the shift towards more convenient, patient-friendly dosing regimens.

First approved by the FDA in 2003, atazanavir revolutionized HIV treatment by offering a potent antiretroviral with a once-daily dosing regimen. This medication's impact stems directly from what is the classification of atazanavir within modern pharmacology, defining its role in managing HIV infection effectively.

First approved in 1996 as a breakthrough in HIV treatment, Crixivan (indinavir) was a landmark medication; however, today, **is CRIXIVAN still used** in clinical practice? The answer is no, as it has been largely discontinued due to significant side effects, complex dosing requirements, and the advent of superior, more tolerable treatments.

Approved by the FDA in 1996, CRIXIVAN represented a major advancement in HIV/AIDS treatment as one of the first protease inhibitors. The action of CRIXIVAN, whose generic name is indinavir, is to target a critical enzyme necessary for the virus's life cycle. It played a crucial role in the development of highly active antiretroviral therapy (HAART).